BPG is committed to discovery and dissemination of knowledge
Basic Study
©The Author(s) 2018.
World J Gastroenterol. Dec 28, 2018; 24(48): 5477-5490
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5477
Figure 6
Figure 6 Conceptual diagram. GSK'843 treatment decreases neutrophil recruitment markers, including CXCL1 and CXCL2, thereby reducing neutrophil recruitment to the tissue. However, RIP3 inhibition increases de novo fat synthesis while decreasing VLDL secretion. RIP3: Receptor interacting protein kinase-3; CXCL1: Chemokine (C-X-C motif) ligand-1; CXCL2: Chemokine (C-X-C motif) ligand-2; VLDL: Very-low-density lipoproteins.


Write to the Help Desk